Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study.

Nat Commun · 2026 · PMC12923573 · PMID 41559089

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

52.8% ± 7.5, p < 0.05), although the latter did not reach statistical significance and also corresponded with a lack of synergy in cell viability.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.